Natera develops cell-free DNA genetic diagnostics across oncology, women's health and organ health, including the Panorama, Signatera and Prospera tests.
Natera is a global developer of cell-free DNA (cfDNA) tests, applying genetic diagnostics across oncology, women's health and organ health. The company's laboratories are ISO 13485-certified, CAP-accredited and CLIA-certified, and its assays are backed by more than 300 peer-reviewed publications. Detection sensitivity reaches down to a single molecule in a tube of blood.
Its product line spans three clinical areas. Panorama™ is a market-leading prenatal screening test. Signatera™ is a personalised cancer detection test. Prospera™ monitors transplant recipients. The tests are intended to identify disease at its earliest stages, allowing earlier and more targeted intervention.
Technical work at the company covers cell-free DNA testing, molecular biology, bioinformatics software, artificial intelligence and single-molecule detection. The stated mission is to make personalised genetic testing and diagnostics part of the standard of care.
Natera operates from Austin, Texas, and San Carlos, California, with a worldwide presence. Further information is available at natera.com.
